Scholarlink

<p>Halogenation enhances the stability and function of pharmaceuticals, biomaterials, and industrial compounds. However, chemical halogenation of molecules and peptides can lack stereoselectivity and require the use of toxic chemicals. Although enzymatic halogenation can improve selectivity and reduce environmental impact, current halogenases are inefficient and insoluble, leading to low yields that limit their applications. Here, we develop RebH<sub>Evo4</sub>, a soluble and highly active tryptophan halogenase, containing 12 mutations that confer 37-fold and 44-fold increases in 7-chloro- and 7-bromotryptophan production respectively, in vivo. To create RebH<sub>Evo4</sub>, we devise an aminoacyl-tRNA synthetase-based halogenase biosensor and conduct over 500 hours of phage-assisted continuous evolution (PACE). Use of RebH<sub>Evo4</sub> in a bioreactor results in the production of 2.7 g/L of halogenated tryptophan. When coupled with a downstream enzyme, RebH<sub>Evo4</sub> allows 36-fold increased yields of halogenated tryptamines compared to the wild-type enzyme. Additionally, RebH<sub>Evo4</sub> enables efficient production of genetically encoded antimicrobial halogenated peptides. The efficient, site-specific halogenation enabled by our evolved halogenase will accelerate sustainable biomanufacturing of halogenated drugs.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Continuous evolution of a halogenase enzyme with improved solubility and activity for sustainable bioproduction

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年3月24日

查看全文
  • Andre Arashiro Pulschen,
  • Justin Booth,
  • Ari Satanowski,
  • Christelle Soudy,
  • Joaquin Caro-Astorga,
  • Osaid Ather,
  • Namita Patel,
  • Ali Alidoust,
  • Samir Aoudjane,
  • Lily Nematollahi,
  • Erika DeBenedictis

摘要

Halogenation enhances the stability and function of pharmaceuticals, biomaterials, and industrial compounds. However, chemical halogenation of molecules and peptides can lack stereoselectivity and require the use of toxic chemicals. Although enzymatic halogenation can improve selectivity and reduce environmental impact, current halogenases are inefficient and insoluble, leading to low yields that limit their applications. Here, we develop RebHEvo4, a soluble and highly active tryptophan halogenase, containing 12 mutations that confer 37-fold and 44-fold increases in 7-chloro- and 7-bromotryptophan production respectively, in vivo. To create RebHEvo4, we devise an aminoacyl-tRNA synthetase-based halogenase biosensor and conduct over 500 hours of phage-assisted continuous evolution (PACE). Use of RebHEvo4 in a bioreactor results in the production of 2.7 g/L of halogenated tryptophan. When coupled with a downstream enzyme, RebHEvo4 allows 36-fold increased yields of halogenated tryptamines compared to the wild-type enzyme. Additionally, RebHEvo4 enables efficient production of genetically encoded antimicrobial halogenated peptides. The efficient, site-specific halogenation enabled by our evolved halogenase will accelerate sustainable biomanufacturing of halogenated drugs.